This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): NVF233, interferon beta-1b
Description: Extavia is a non-glycosylated recombinant human interferon-beta approved for high-frequency, subcutaneous administration (injection) in the treatment of multiple sclerosis.
Deal Structure: Chiron and Berlex, a subsidiary of Schering AG, jointly developed betaseron. Under their agreement, which originated in 1993, betaseron was manufactured by Chiron and sold outside of Europe by Berlex and Schering. Chiron also received royalties from European sales of an identical product, manufactured by Boehringer Ingelheim and sold by Schering. In 2006, Novartis acquired Chiron and Bayer acquired Schering AG.
The collaboration agreement between Chiron and Schering was set to expire in October 2008. In March 2007, Novartis and Bayer signed an agreement that would provide Novartis the opportunity to introduce in the first half of 2009 its own branded version of interferon beta-1b (NVF233 or Extavia). Bayer would assume manufacturing responsibility for its own interferon beta 1b from Novartis and supply Novartis with this product for the latter's branded version in return for a double-digit royalty payment. Novartis...See full deal structure in Biomedtracker
Additional information available to subscribers only: